Advances in Antifungal Drug Development: An Up-To-Date Mini Review
Pharmaceuticals, 2021 The utility of clinically available antifungals is limited by their narrow spectrum of activity, high toxicity, and emerging resistance. Antifungal drug discovery has always been a challenging area, since fungi and their human host are eukaryotes, making
Ghada Bouz, Martin Doležal
doaj +1 more source
Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates [PDF]
, 2015 The limited armamentarium of active and oral antifungal drugs against emerging non-Aspergillus molds is of particular concern. Current antifungal agents and the new orally available beta-1,3-d-glucan synthase inhibitor SCY-078 were tested in vitro ...
Frédéric Lamoth +3 more
core +1 more source
Genome-wide investigation of cellular targets and mode of action of the antifungal bacterial metabolite 2,4-diacetylphloroglucinol in Saccharomyces cerevisiae [PDF]
, 2013 Saccharomyces cerevisiae is a proven model to investigate the effects of small molecules and drugs on fungal and eukaryotic cells. In this study, the mode of action of an antifungal metabolite, 2,4-diacetylphloroglucinol (DAPG), was determined.
Troppens, Danielle M. +9 more
core +1 more source
Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges
Frontiers in Cellular and Infection Microbiology, 2020 Opportunistic fungal infections are major causes of morbidity and mortality in patients with single or multiple defects in their immunity. Antifungal agents targeting the pathogen remain the treatment of choice for fungal infections.
Muluneh Ademe
doaj +1 more source
New Antifungal Agents with Azole Moieties
Pharmaceuticals, 2022 Fungal conditions affect a multitude of people worldwide, leading to increased hospitalization and mortality rates, and the need for novel antifungals is emerging with the rise of resistance and immunocompromised patients.
Melissa Martins Teixeira +3 more
doaj +1 more source
Pharmaceutics, 2020 Pulmonary aspergillosis (PA), a pulmonary fungal infection caused by Aspergillus spp., is a concern for immunocompromised populations. Despite substantial research efforts, conventional treatments of PA using antifungal agents are associated with ...
Shen Nam Cheng +6 more
doaj +1 more source
Antifungal Application of Nonantifungal Drugs [PDF]
, 2014 Candida species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to similar to 150,000 deaths annually due to systemic infections, whereas the current antifungal therapies either have toxic side effects or are insufficiently ...
Wennerberg, Krister +9 more
core +1 more source
Natural antifungal agents for food preservation [PDF]
Benha Veterinary Medical Journal, 2020 The increasing societal demand for less processed and more natural food products—while conserving those products’ quality, safety, and shelf-life—has raised the question of chemical preservative replacement. In this context, bacteria and fungi as well as
Mahmoud Hammad +2 more
doaj +1 more source
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Frontiers in Cellular and Infection MicrobiologyFungal infections pose a significant threat to human health, particularly in immunocompromised individuals, driving a sustained increase in the demand for effective antifungal agents.
Yanjian Li +7 more
doaj +1 more source
Candida Glabrata Fungaemia in a Tertiary Centre in Taiwan: Antifungal Susceptibility and Outcomes [PDF]
, 2011 The proportion of non-albicans candidaemia has increased during recent decades, especially Candida glabrata. We evaluated the antifungal susceptibility, clinical features and outcome of C. glabrata fungaemia treated in a tertiary centre in Taiwan.
RUAN, SHENG-YUAN;HUANG, YU-TSUNG;CHU, CHEN-CHEN;YU, CHONG-JEN;HSUEH, PO-REN +1 more
core +1 more source